Business Context and Reporting Period
This Form 8-K is a current report filed by Mustang Bio, Inc. on December 11, 2023. The filing addresses significant changes in the company's executive leadership following the unexpected passing of the Interim Chief Financial Officer.
Key Financial Metrics
This filing does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Departure of Officer: Eliot Lurier, who served as Interim Chief Financial Officer since April 2022, passed away unexpectedly on December 8, 2023.
- Appointment of Interim CFO: Manuel Litchman, M.D., the company's President and Chief Executive Officer, was appointed as Interim Chief Financial Officer effective December 11, 2023.
- Appointment of Interim CAO: Peter Carney, the company's Controller since August 2021, was appointed as Interim Chief Accounting Officer effective December 11, 2023.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks beyond the leadership transition. Management confirmed that no new compensation plans, arrangements, or employment agreements were entered into with Dr. Litchman or Mr. Carney in connection with these appointments. No family relationships or material interests requiring disclosure under Regulation S-K were identified.
Investor Verification Checklist
- Verify the effective dates of the new interim appointments (December 11, 2023).
- Confirm that no additional compensation was granted for the new roles.
- Review subsequent filings for the appointment of a permanent Chief Financial Officer.
- Check for any impact on the company's financial reporting timeline due to the leadership change.